Symbols / CLGN Stock $0.41 +7.23% CollPlant Biotechnologies Ltd.

Healthcare • Biotechnology • Israel • NCM
CLGN (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Yehiel Tal
Exch · Country NCM · Israel
Market Cap 5.92M
Enterprise Value 3.17M
Income -11.49M
Sales 2.37M
FCF (ttm) -5.48M
Book/sh 0.47
Cash/sh 0.39
Employees 39
Insider 10d —
IPO Jan 31, 2018
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -1.05
PEG —
P/S 2.50
P/B 0.86
P/C —
EV/EBITDA -0.30
EV/Sales 1.34
Quick Ratio 2.18
Current Ratio 2.52
Debt/Eq 46.80
LT Debt/Eq —
EPS (ttm) -0.94
EPS next Y -0.39
EPS Growth —
Revenue Growth -63.40%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-27
Earnings (prior) 2026-03-26
ROA -48.67%
ROE -117.56%
ROIC —
Gross Margin 64.78%
Oper. Margin -52.50%
Profit Margin 0.00%
Shs Outstand 14.42M
Shs Float 10.14M
Insider Own 26.88%
Instit Own 10.95%
Short Float 0.62%
Short Ratio 0.70
Short Interest 65.69K
52W High 4.98
vs 52W High -91.76%
52W Low 0.27
vs 52W Low 51.51%
Beta 0.94
Impl. Vol. 21.25%
Rel Volume 0.23
Avg Volume 127.73K
Volume 29.12K
Target (mean) —
Tgt Median —
Tgt Low —
Tgt High —
# Analysts —
Recom None
Prev Close $0.38
Price $0.41
Change 7.23%
About

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on its recombinant human collagen (rhCollagen) that is produced using its proprietary technology. The company offers regenerative dermal and soft tissue fillers; 3D-bioprinted regenerative breast implants; Collage, a combinant human Collagen type I solution; VergenixSTR, a soft tissue matrix for the treatment of tendinopathy; and VergenixFG, a wound care product for the treatment of deep surgical incisions and deep wounds. It also provides rhcollagen-based commercial bioink for regenerative medicine applications, such as Collink.3D 50L, a bioink in powder form; Collink.3D 90, an rhCollagen-based bioink solution for use in various 3D bioprinting applications; and Collink.3D 50, an rhCollagen-based bioink product. The company has collaboration agreements with AbbVie; STEMCELL; the Advanced Regenerative Manufacturing Institute; Stratasys; and RegenMed Development Organization. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. CollPlant Biotechnologies Ltd. was founded in 2004 and is headquartered in Rehovot, Israel.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
—
Mean price target
2. Current target
$0.41
Latest analyst target
3. DCF / Fair value
$-6.84
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.41
Low
—
High
—
Mean
—

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-02-06 down D. Boral Capital Buy → Hold —
2025-11-28 main D. Boral Capital Buy → Buy $12
2025-10-20 main D. Boral Capital Buy → Buy $12
2025-09-16 main D. Boral Capital Buy → Buy $12
2025-08-21 reit HC Wainwright & Co. Buy → Buy $11
2025-08-20 main D. Boral Capital Buy → Buy $12
2025-05-30 main D. Boral Capital Buy → Buy $12
2025-05-28 main D. Boral Capital Buy → Buy $12
2025-03-27 main D. Boral Capital Buy → Buy $14
2025-02-12 main D. Boral Capital Buy → Buy $14
2025-02-04 main D. Boral Capital Buy → Buy $14
2024-11-29 reit HC Wainwright & Co. Buy → Buy $11
2024-11-27 main D. Boral Capital Buy → Buy $14
2024-08-21 reit HC Wainwright & Co. Buy → Buy $11
2024-08-20 main EF Hutton Buy → Buy $14
2024-08-05 init EF Hutton — → Buy $14
2024-05-30 reit HC Wainwright & Co. Buy → Buy $11
2024-04-05 reit HC Wainwright & Co. Buy → Buy $11
2023-11-30 reit HC Wainwright & Co. Buy → Buy $11
2023-08-25 reit HC Wainwright & Co. Buy → Buy $11
News
RSS: Latest CLGN news
Insider Transactions

No recent insider transactions.

Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
2.37
+360.39%
0.52
-95.30%
10.96
+3565.22%
0.30
Operating Revenue
2.37
+360.39%
0.52
-95.30%
10.96
+3565.22%
0.30
Cost Of Revenue
0.83
-48.62%
1.62
-18.38%
1.99
+397.75%
0.40
Reconciled Cost Of Revenue
0.83
-48.62%
1.62
-18.38%
1.99
+397.75%
0.40
Gross Profit
1.54
+238.38%
-1.11
-112.38%
8.97
+8979.21%
-0.10
Operating Expense
13.02
-19.34%
16.14
-2.06%
16.48
-3.04%
17.00
Research And Development
8.19
-22.14%
10.52
+0.30%
10.48
+2.23%
10.26
Selling General And Administration
4.83
-14.11%
5.63
-6.17%
6.00
-11.05%
6.74
Total Expenses
13.85
-22.02%
17.77
-3.82%
18.47
+6.18%
17.40
Operating Income
-11.48
+33.44%
-17.25
-129.65%
-7.51
+56.06%
-17.10
Total Operating Income As Reported
-11.48
+33.44%
-17.25
-129.65%
-7.51
+56.06%
-17.10
EBITDA
-10.57
+34.80%
-16.21
-152.93%
-6.41
+59.99%
-16.02
Normalized EBITDA
-10.20
+36.78%
-16.13
-163.41%
-6.12
+61.49%
-15.91
Reconciled Depreciation
0.91
-12.14%
1.04
-5.81%
1.10
+2.42%
1.08
EBIT
-11.48
+33.44%
-17.25
-129.65%
-7.51
+56.06%
-17.10
Total Unusual Items
-0.37
-369.62%
-0.08
+72.28%
-0.28
-147.83%
-0.12
Total Unusual Items Excluding Goodwill
-0.37
-369.62%
-0.08
+72.28%
-0.28
-147.83%
-0.12
Net Income
-11.49
+30.83%
-16.61
-136.63%
-7.02
+58.53%
-16.93
Pretax Income
-11.49
+30.83%
-16.61
-136.63%
-7.02
+58.53%
-16.93
Net Non Operating Interest Income Expense
0.36
-49.38%
0.72
-7.33%
0.78
+171.08%
0.29
Net Interest Income
0.36
-49.38%
0.72
-7.33%
0.78
+171.08%
0.29
Interest Income Non Operating
0.38
-48.51%
0.74
-6.35%
0.79
+145.48%
0.32
Interest Income
0.38
-48.51%
0.74
-6.35%
0.79
+145.48%
0.32
Other Income Expense
-0.37
-369.62%
-0.08
+72.28%
-0.28
-147.83%
-0.12
Gain On Sale Of Security
-0.37
-369.62%
-0.08
+72.28%
-0.28
-147.83%
-0.12
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-11.49
+30.83%
-16.61
-136.63%
-7.02
+58.53%
-16.93
Net Income From Continuing Operation Net Minority Interest
-11.49
+30.83%
-16.61
-136.63%
-7.02
+58.53%
-16.93
Net Income From Continuing And Discontinued Operation
-11.49
+30.83%
-16.61
-136.63%
-7.02
+58.53%
-16.93
Net Income Continuous Operations
-11.49
+30.83%
-16.61
-136.63%
-7.02
+58.53%
-16.93
Normalized Income
-11.12
+32.74%
-16.53
-145.47%
-6.73
+59.94%
-16.81
Net Income Common Stockholders
-11.49
+30.83%
-16.61
-136.63%
-7.02
+58.53%
-16.93
Diluted EPS
—
-1.45
-133.87%
-0.62
+59.48%
-1.53
Basic EPS
—
-1.45
-133.87%
-0.62
+59.48%
-1.53
Basic Average Shares
—
11.45
+0.57%
11.39
+3.23%
11.03
Diluted Average Shares
—
11.45
+0.57%
11.39
+3.23%
11.03
Diluted NI Availto Com Stockholders
-11.49
+30.83%
-16.61
-136.63%
-7.02
+58.53%
-16.93
Total Other Finance Cost
0.01
-11.76%
0.02
+70.00%
0.01
-70.59%
0.03
Line Item Trend 2024-12-31 2023-12-31
Total Assets
18.71
-45.17%
34.13
Current Assets
13.18
-52.97%
28.02
Cash Cash Equivalents And Short Term Investments
11.91
-55.35%
26.67
Cash And Cash Equivalents
11.91
-55.35%
26.67
Other Short Term Investments
—
—
Receivables
0.58
+48.35%
0.39
Accounts Receivable
0.15
0.00
Other Receivables
0.43
+10.18%
0.39
Inventory
0.44
-38.38%
0.71
Work In Process
0.29
+65.32%
0.17
Finished Goods
0.15
-71.53%
0.54
Restricted Cash
0.25
+2.90%
0.24
Total Non Current Assets
5.53
-9.40%
6.10
Net PPE
5.28
-9.87%
5.86
Gross PPE
12.30
+3.36%
11.90
Accumulated Depreciation
-7.02
-16.18%
-6.05
Properties
0.00
0.00
Machinery Furniture Equipment
0.87
+7.26%
0.81
Other Properties
7.78
+2.56%
7.59
Leases
3.65
+4.20%
3.50
Goodwill And Other Intangible Assets
0.13
-30.32%
0.19
Other Non Current Assets
0.12
+107.02%
0.06
Total Liabilities Net Minority Interest
5.25
-9.35%
5.79
Current Liabilities
2.97
-8.64%
3.25
Payables And Accrued Expenses
0.97
-10.51%
1.08
Payables
0.97
-0.92%
0.98
Accounts Payable
0.87
-11.22%
0.98
Other Payable
0.10
-3.81%
0.10
Current Accrued Expenses
0.10
-3.81%
0.10
Pensionand Other Post Retirement Benefit Plans Current
1.19
-22.63%
1.54
Current Debt And Capital Lease Obligation
0.81
+29.17%
0.62
Current Capital Lease Obligation
0.81
+29.17%
0.62
Current Deferred Liabilities
—
—
Current Deferred Revenue
—
—
Total Non Current Liabilities Net Minority Interest
2.27
-10.26%
2.54
Long Term Debt And Capital Lease Obligation
2.27
-10.26%
2.54
Long Term Capital Lease Obligation
2.27
-10.26%
2.54
Stockholders Equity
13.46
-52.49%
28.34
Common Stock Equity
13.46
-52.49%
28.34
Capital Stock
4.98
+0.02%
4.98
Common Stock
4.98
+0.02%
4.98
Share Issued
11.47
+0.02%
11.47
Ordinary Shares Number
11.45
+0.02%
11.45
Treasury Shares Number
0.02
+0.00%
0.02
Additional Paid In Capital
122.80
+1.43%
121.07
Retained Earnings
-113.35
-17.17%
-96.74
Gains Losses Not Affecting Retained Earnings
-0.97
+0.00%
-0.97
Other Equity Adjustments
-0.97
+0.00%
-0.97
Total Equity Gross Minority Interest
13.46
-52.49%
28.34
Total Capitalization
13.46
-52.49%
28.34
Working Capital
10.21
-58.78%
24.77
Invested Capital
13.46
-52.49%
28.34
Total Debt
3.08
-2.47%
3.16
Capital Lease Obligations
3.08
-2.47%
3.16
Net Tangible Assets
13.33
-52.64%
28.15
Tangible Book Value
13.33
-52.64%
28.15
Current Provisions
—
—
Derivative Product Liabilities
—
—
Foreign Currency Translation Adjustments
—
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-9.42
+33.17%
-14.09
-410.06%
-2.76
+79.83%
-13.70
Cash Flow From Continuing Operating Activities
-9.42
+33.17%
-14.09
-410.06%
-2.76
+79.83%
-13.70
Net Income From Continuing Operations
-11.49
+30.83%
-16.61
-136.63%
-7.02
+58.53%
-16.93
Depreciation Amortization Depletion
0.91
-12.14%
1.04
-5.81%
1.10
+2.42%
1.08
Depreciation
—
—
—
—
Depreciation And Amortization
0.91
-12.14%
1.04
-5.81%
1.10
+2.42%
1.08
Other Non Cash Items
-0.01
-36.36%
-0.01
+60.71%
-0.03
+67.82%
-0.09
Stock Based Compensation
1.00
-41.88%
1.72
-11.25%
1.94
-10.90%
2.17
Operating Gains Losses
-0.08
-156.34%
0.14
-64.23%
0.40
-34.70%
0.61
Gain Loss On Investment Securities
—
—
—
—
Net Foreign Currency Exchange Gain Loss
-0.08
-156.34%
0.14
-62.53%
0.38
-37.66%
0.61
Gain Loss On Sale Of PPE
0.00
0.00
-100.00%
0.02
0.00
Change In Working Capital
0.25
+168.28%
-0.37
-143.87%
0.85
+255.88%
-0.54
Change In Receivables
0.36
+288.95%
-0.19
-219.50%
0.16
+11.97%
0.14
Changes In Account Receivables
0.15
+199.33%
-0.15
-1766.67%
0.01
-96.55%
0.26
Change In Inventory
-0.13
-146.07%
0.28
-62.62%
0.75
+340.06%
-0.31
Change In Prepaid Assets
—
—
0.15
+226.05%
-0.12
Change In Payables And Accrued Expense
-0.31
+33.91%
-0.46
-1007.84%
0.05
-54.87%
0.11
Change In Accrued Expense
-0.05
+86.97%
-0.35
-273.04%
0.20
+1357.14%
0.01
Change In Payable
-0.26
-136.36%
-0.11
+28.10%
-0.15
-254.55%
0.10
Change In Account Payable
-0.26
-136.36%
-0.11
+28.10%
-0.15
-254.55%
0.10
Change In Other Working Capital
—
—
—
-0.03
Change In Other Current Assets
0.67
+2.30%
0.65
+23.53%
0.53
+14.32%
0.46
Change In Other Current Liabilities
-0.34
+48.31%
-0.65
-1.88%
-0.64
+30.35%
-0.92
Investing Cash Flow
-0.03
+94.99%
-0.54
+53.37%
-1.16
-104.00%
28.92
Cash Flow From Continuing Investing Activities
-0.03
+94.99%
-0.54
+53.37%
-1.16
-104.00%
28.92
Net PPE Purchase And Sale
-0.03
+94.40%
-0.48
+45.60%
-0.89
+30.46%
-1.27
Purchase Of PPE
-0.03
+94.20%
-0.48
+49.37%
-0.95
+25.12%
-1.27
Sale Of PPE
0.00
+0.00%
0.00
-98.53%
0.07
0.00
Capital Expenditure
-0.03
+94.20%
-0.48
+49.37%
-0.95
+27.51%
-1.32
Capital Expenditure Reported
—
—
—
-0.04
Net Investment Purchase And Sale
—
0.00
0.00
-100.00%
30.24
Purchase Of Investment
—
0.00
0.00
+100.00%
-20.00
Sale Of Investment
—
0.00
0.00
-100.00%
50.24
Net Intangibles Purchase And Sale
—
0.00
0.00
+100.00%
-0.04
Purchase Of Intangibles
—
0.00
0.00
+100.00%
-0.04
Net Other Investing Changes
—
-0.06
+78.89%
-0.27
—
Financing Cash Flow
3.10
+34366.67%
0.01
-99.19%
1.11
-40.88%
1.87
Cash Flow From Continuing Financing Activities
3.10
+34366.67%
0.01
-99.19%
1.11
-40.88%
1.87
Net Issuance Payments Of Debt
—
—
—
0.00
Repayment Of Debt
—
—
—
0.00
Long Term Debt Payments
—
—
—
0.00
Net Long Term Debt Issuance
—
—
—
0.00
Net Common Stock Issuance
3.10
0.00
0.00
0.00
Proceeds From Stock Option Exercised
0.00
-100.00%
0.01
-99.19%
1.11
-40.88%
1.87
Changes In Cash
-6.34
+56.62%
-14.62
-420.21%
-2.81
-116.44%
17.10
Effect Of Exchange Rate Changes
0.03
+118.31%
-0.14
+62.53%
-0.38
+37.66%
-0.61
Beginning Cash Position
11.91
-55.35%
26.67
-10.68%
29.86
+123.30%
13.37
End Cash Position
5.59
-53.05%
11.91
-55.35%
26.67
-10.68%
29.86
Free Cash Flow
-9.45
+35.19%
-14.58
-292.14%
-3.72
+75.24%
-15.01
Income Tax Paid Supplemental Data
0.02
-74.19%
0.06
+675.00%
0.01
-74.19%
0.03
Common Stock Issuance
3.10
0.00
0.00
0.00
Issuance Of Capital Stock
3.10
0.00
0.00
0.00
SEC Filings

No SEC filings found for this symbol (may be non-US or ticker not in SEC index).

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category